Abstract
Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Current Proteomics
Title: Toxicoproteomics: Applications in Drug Development
Volume: 2 Issue: 2
Author(s): N. Gupta, A. Law, R. Poddar, M. Louie, A. Ray and D. N. Chakravarti
Affiliation:
Keywords: proteomics, toxicoproteomics, drug toxicology, personalized medicine, hepatotoxicity, nephrotoxicity
Abstract: Toxicoproteomics is the study of the effects of chemical exposure on tissues through identification and quantitative evaluation of changes occurring in the proteome profile. This approach has been and continues to be applied in the preclinical testing of drugs for precise as well as high-throughput determination of toxic effects. Several investigations have indicated that use of proteomics can lead to successful identification of potentially toxic compounds earlier in the drug development process. This review covers recent studies that have used simultaneous measurement of multiple protein markers for prediction of tissue toxicities. In addition, conventional and newer proteomic techniques have been evaluated for applicability to drug toxicology studies. The potential of toxicoproteomics to predict adverse drug reactions in clinical use have also been explored.
Export Options
About this article
Cite this article as:
Gupta N., Law A., Poddar R., Louie M., Ray A. and Chakravarti N. D., Toxicoproteomics: Applications in Drug Development, Current Proteomics 2005; 2 (2) . https://dx.doi.org/10.2174/1570164054494181
DOI https://dx.doi.org/10.2174/1570164054494181 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of ABC and SLC Transporters in the Pharmacokinetics of Dietary and Herbal Phytochemicals and their Interactions with Xenobiotics
Current Drug Metabolism Protein Targets for Anticancer Gold Compounds: Mechanistic Inferences
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Dissecting Insulin Signaling Pathways: Individualised Therapeutic Targets for Diagnosis and Treatment of Insulin Resistant States
Endocrine, Metabolic & Immune Disorders - Drug Targets New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Improving the Stability of Aptamers by Chemical Modification
Current Medicinal Chemistry Patents in miRNAs Biomarkers for Gastrointestinal Cancer Diagnostics
Recent Patents on Biomarkers Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Anti-Cancer Potential of Some Commonly Used Drugs
Current Pharmaceutical Design